The role of plasma volume, plasma renin and the sympathetic nervous system in the posture-induced decline in renal lithium clearance in man.
Excretion of lithium in urine was studied in 2 healthy males while recumbent and while upright, either walking or standing quietly. An oral dose of 24.3 mmol of Lit was taken as three lithium carbonate tablets 13 h before clearance tests. Renal lithium clearance decreased and lithium fractional reabsorption increased while upright. Standing immersed to the neck in water, which prevents the fall in plasma volume upon changing posture from recumbent to upright, prevented the fall in renal lithium clearance as well as the rise in lithium fractional reabsorption while upright. Oral doses of guanethidine (total dose of 200 mg) or oxprenolol (total dose of 140 mg) taken to prevent high levels of sympathetic nervous system activity and plasma renin, respectively, failed to prevent the fall in renal lithium clearance or the rise in lithium fractional reabsorption upon changing posture from recumbent to upright. The findings indicate that the fall in renal lithium clearance and the rise in lithium fractional reabsorption upon changing posture from recumbent to upright is related to the fall in plasma volume but not to high levels of sympathetic nervous system activity or plasma renin activity.
D000042:Absorption; D000328:Adult; D006145:Guanethidine / Q000494:pharmacology; D006801:Humans; D007101:Immersion; D008094:Lithium / Q000378:metabolism / Q000652:urine*; D008297:Male; D008657:Metabolic Clearance Rate; D009068:Movement; D010096:Oxprenolol / Q000494:pharmacology; D010953:Plasma Volume; D011187:Posture; D012083:Renin / Q000097:blood*; D013564:Sympathetic Nervous System / Q000502:physiology*; D013696:Temperature
D010096:Oxprenolol; D008094:Lithium; D012083:Renin; D006145:Guanethidine